AHI Nasdaq Delisting Party, page-20

Digital scans are very exciting and hopefully AHI (and other companies) will make huge inroads. I just looked up their technology and they show this for their Dermascan:


A sensitivity of 73% implies a 27% false negative rate. That is, 27% of users will have condition 'X" that the technology can't detect. (FWIW, industry standards of sensitivity and specificity around 90% are desirable). Approx quarter of users will get a false sense of security, IF they use this in isolation. I was rather shocked by this data and it only goes to show a second opinion is super critical, particularly where skin cancers are of concern. Having had 15 skin cancers myself, I think I will go to the dermatologist.